101 related articles for article (PubMed ID: 23075235)
21. The quest for reliable biomarkers to identify new and recurrent cancer.
Sauter ER
Biomark Med; 2012 Oct; 6(5):561-2. PubMed ID: 23075234
[No Abstract] [Full Text] [Related]
22. The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice.
Marshall D; Laberge JM; Firetag B; Miller T; Kerlan RK
J Vasc Interv Radiol; 2013 Aug; 24(8):1094-103. PubMed ID: 23806383
[TBL] [Abstract][Full Text] [Related]
23. Molecular cancer diagnostics.
Marte B; Eccleston A; Nath D
Nature; 2008 Apr; 452(7187):547. PubMed ID: 18385727
[No Abstract] [Full Text] [Related]
24. Genomics, personalized medicine and cancer practice.
Dancey J
Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082
[No Abstract] [Full Text] [Related]
25. Enabling personalized cancer medicine through analysis of gene-expression patterns.
van't Veer LJ; Bernards R
Nature; 2008 Apr; 452(7187):564-70. PubMed ID: 18385730
[TBL] [Abstract][Full Text] [Related]
26. [Molecular markers of malignant tumors].
Shelepova VM; Kadagidze ZG; Shevchenko VE; Likhtenshteĭn AV
Patol Fiziol Eksp Ter; 2008; (4):2-5. PubMed ID: 19202613
[No Abstract] [Full Text] [Related]
27. A pathway-based approach to identify molecular biomarkers in cancer.
Stevenson M; Potti A
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S620-4. PubMed ID: 22048630
[TBL] [Abstract][Full Text] [Related]
28. [Use of molecular genetic analysis in selecting antitumor therapy].
Imianitov EN; Moiseenko VM
Vopr Onkol; 2008; 54(2):121-32. PubMed ID: 18522159
[No Abstract] [Full Text] [Related]
29. Surmounting chemoresistance by targeting the Y-box binding protein-1.
Inoue I; Matsumoto K; Yu Y; Bay BH
Anat Rec (Hoboken); 2012 Feb; 295(2):215-22. PubMed ID: 22190445
[TBL] [Abstract][Full Text] [Related]
30. Systematic classification of melanoma cells by phenotype-specific gene expression mapping.
Widmer DS; Cheng PF; Eichhoff OM; Belloni BC; Zipser MC; Schlegel NC; Javelaud D; Mauviel A; Dummer R; Hoek KS
Pigment Cell Melanoma Res; 2012 May; 25(3):343-53. PubMed ID: 22336146
[TBL] [Abstract][Full Text] [Related]
31. SnapShot: MicroRNAs in Cancer.
Spizzo R; Nicoloso MS; Croce CM; Calin GA
Cell; 2009 May; 137(3):586-586.e1. PubMed ID: 19410551
[No Abstract] [Full Text] [Related]
32. Pre-analytical variables in miRNA analysis.
Becker N; Lockwood CM
Clin Biochem; 2013 Jul; 46(10-11):861-8. PubMed ID: 23466658
[TBL] [Abstract][Full Text] [Related]
33. Splicing factors are differentially expressed in tumors.
Kirschbaum-Slager N; Lopes GM; Galante PA; Riggins GJ; de Souza SJ
Genet Mol Res; 2004 Dec; 3(4):512-20. PubMed ID: 15688317
[TBL] [Abstract][Full Text] [Related]
34. Using kallikrein-related peptidases (KLK) as novel cancer biomarkers.
Schmitt M; Magdolen V
Thromb Haemost; 2009 Feb; 101(2):222-4. PubMed ID: 19190801
[No Abstract] [Full Text] [Related]
35. Correlation of ErbB2 gene status, mRNA and protein expression.
D'Incalci M
Onkologie; 2006 Jun; 29(6):246-7. PubMed ID: 16770085
[No Abstract] [Full Text] [Related]
36. Cancer: an epigenetic landscape.
Dhanasekaran K; Arif M; Kundu TK
Subcell Biochem; 2013; 61():399-417. PubMed ID: 23150260
[No Abstract] [Full Text] [Related]
37. The potential role of podoplanin in tumour invasion.
Wicki A; Christofori G
Br J Cancer; 2007 Jan; 96(1):1-5. PubMed ID: 17179989
[TBL] [Abstract][Full Text] [Related]
38. Gene expression 'signature' limitations and genome architecture-based perspectives for robust cancer biomarkers.
Katsios CS; Papaloukas C; Roukos DH; Baltogiannis G
Biomark Med; 2013 Feb; 7(1):79-82. PubMed ID: 23387487
[No Abstract] [Full Text] [Related]
39. The cancer biomarker problem.
Sawyers CL
Nature; 2008 Apr; 452(7187):548-52. PubMed ID: 18385728
[TBL] [Abstract][Full Text] [Related]
40. The epigenome and cancer prevention: A complex story of dietary supplementation.
Lee HS; Herceg Z
Cancer Lett; 2014 Jan; 342(2):275-84. PubMed ID: 22266189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
